Abstract
Predicting individual response to drug therapy has long been a goal of personalized medicine in every therapeutic area. The mapping of the human genome and subsequent advancements in genetic technology had raised the public expectation that personalized drug therapy would come sooner than later. However, with barriers and logistical challenges existing at multiple levels, achieving this goal remains years away. Knowledge gap in healthcare professionals has always been cited as a significant barrier in clinical implementation of pharmacogenomics. Yet, to overcome the spectrum of challenges and for personalized medicine to succeed, there needs to be a rethinking of expanding the educational scope to include all stakeholders within the personalized medicine innovation ecosystem, rather than “narrowly” focusing on simply educating current and future health practitioners. Personalized medicine can only be achieved with all stakeholders in the field, under the rubric of a vision of a “knowledge ecosystem”, working together, and occasionally accepting a paradigm change in their current approaches to implementation. If postgenomics personalized medicine is to embrace systems pharmacology as a core tenet, it seems essential that such broader vision should be extended to field of education as well.
Keywords: Education, healthcare professionals, innovation ecosystem, personalized medicine, public health pharmacogenomics, stakeholders, systems pharmacology.
Current Pharmacogenomics and Personalized Medicine
Title:Rethinking Pharmacogenomics Education Beyond Health Professionals: Addressing the “Know-Do” Gap Across the Personalized Medicine Innovation Ecosystem
Volume: 10
Author(s): Y. W. Francis Lam
Affiliation:
Keywords: Education, healthcare professionals, innovation ecosystem, personalized medicine, public health pharmacogenomics, stakeholders, systems pharmacology.
Abstract: Predicting individual response to drug therapy has long been a goal of personalized medicine in every therapeutic area. The mapping of the human genome and subsequent advancements in genetic technology had raised the public expectation that personalized drug therapy would come sooner than later. However, with barriers and logistical challenges existing at multiple levels, achieving this goal remains years away. Knowledge gap in healthcare professionals has always been cited as a significant barrier in clinical implementation of pharmacogenomics. Yet, to overcome the spectrum of challenges and for personalized medicine to succeed, there needs to be a rethinking of expanding the educational scope to include all stakeholders within the personalized medicine innovation ecosystem, rather than “narrowly” focusing on simply educating current and future health practitioners. Personalized medicine can only be achieved with all stakeholders in the field, under the rubric of a vision of a “knowledge ecosystem”, working together, and occasionally accepting a paradigm change in their current approaches to implementation. If postgenomics personalized medicine is to embrace systems pharmacology as a core tenet, it seems essential that such broader vision should be extended to field of education as well.
Export Options
About this article
Cite this article as:
Lam W. Francis Y., Rethinking Pharmacogenomics Education Beyond Health Professionals: Addressing the “Know-Do” Gap Across the Personalized Medicine Innovation Ecosystem, Current Pharmacogenomics and Personalized Medicine 2012; 10 (4) . https://dx.doi.org/10.2174/187569212803901828
DOI https://dx.doi.org/10.2174/187569212803901828 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bioactive Natural Compounds from the Mangrove Endophytic Fungi
Mini-Reviews in Medicinal Chemistry Tumor in 3D: <i>In Vitro</i> Complex Cellular Models to Improve Nanodrugs Cancer Therapy
Current Medicinal Chemistry Editorial [Hot topic: Models and Evolution of Inflammatory Activities (Executive Editor: Giuseppe Scapigliati)]
Current Pharmaceutical Design Third Generation Radiopharmaceuticals for Imaging and Targeted Therapy
Current Pharmaceutical Analysis Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters The Application of Fungal Beta-glucans for the Treatment of Colon Cancer
Anti-Cancer Agents in Medicinal Chemistry Role of NF-κB and NF-κB-regulated Gene Products in Chemoresistance and Radioresistance
Current Cancer Therapy Reviews Old and New Gasotransmitters in the Cardiovascular System: Focus on the Role of Nitric Oxide and Hydrogen Sulfide in Endothelial Cells and Cardiomyocytes
Current Pharmaceutical Biotechnology Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Current Drug Delivery Potential Therapeutic Agents from the Red Sea Organisms
Medicinal Chemistry Current Insights into Interethnic Variability in Testicular Cancers: Population Pharmacogenetics, Clinical Trials, Genetic Basis of Chemotherapy- Induced Toxicities and Molecular Signal Transduction
Current Topics in Medicinal Chemistry Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Current Medicinal Chemistry Transdermal Penetration of Cytarabine and Its 5-O Alkyl Ester Derivatives
Medicinal Chemistry Kinetics of Vascular Targeted Monoclonal Antibody
Current Drug Delivery The Role of the Oxysterol/EBI2 Pathway in the Immune and Central Nervous Systems
Current Drug Targets Virus, Oncolytic Virus and Human Prostate Cancer
Current Cancer Drug Targets Regulatory Roles of the Ubiquitin-Proteasome System in Cardiomyocyte Apoptosis
Current Molecular Medicine The Anandamide Degradation System as Potential Target for the Treatment of Central Nervous System Related Disorders
Current Medicinal Chemistry - Central Nervous System Agents Utility of DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndromes
Current Pharmaceutical Design Endometriosis and Gynecological Cancer
Current Women`s Health Reviews